# Folia Health: The Home-Reported Outcomes Company

> Folia Health is a Boston health technology company that helps patients and caregivers turn everyday symptoms, treatments and disease impacts into structured home-reported outcomes. Its free app provides tracking, graphs and shareable reports; research partnerships fund the business and eligible participants can receive compensation for contributing data.

- **Founded:** 2016
- **Headquarters:** Boston, United States
- **Founders:** Nell Meosky Luo (Founder and CEO), Daniel Toffling (Co-founder and CTO)
- **Products:** Folia app, Home-Reported Outcomes research services, Data Dividends, Canopy Series, Mosaic
- **Notable:** Launched Data Dividends in September 2019., Homepage reports 4.5 million shared home-reported outcomes., Published research portfolio spans nephrology, hematology, dermatology, metabolic and respiratory conditions.

## Products & services

- **Folia app** — Free mobile and web health tracking with customizable symptom and treatment questions, flare tracking, graphs and exportable reports.
- **Home-Reported Outcomes research services** — Research design, recruitment, e-consent, validated ePRO deployment, data hosting, linkage, analysis and publication support for life sciences and advocacy partners.
- **Data Dividends** — Compensation for qualifying U.S. patients and caregivers who consent to general research sharing and meet tracking requirements; up to $48 annually, paid quarterly under published terms.
- **Canopy Series** — User-led research initiative focused on questions from the patient community.
- **Mosaic** — Community insights initiative allowing participants to ask questions answered with aggregated data from people with similar conditions; active in eczema and PNH at the October 2025 announcement.

## Achievements

- Launched Data Dividends in September 2019.
- Homepage reports 4.5 million shared home-reported outcomes.
- Published research portfolio spans nephrology, hematology, dermatology, metabolic and respiratory conditions.
- Reported NPS increasing from 31 in 2023 to 43 in 2025; company-reported measure.
- Raised a $10.5 million Series A in October 2025.

## Latest updates

- **2025-03** — Announced a remote IgAN observational study with Novartis on March 13.
- **2025-04** — Announced a partnership with Inspire on April 30 to build longitudinal real-world evidence communities.
- **2025-10** — Announced a $10.5 million Series A led by S3 Ventures; described Mosaic as active in eczema and PNH.
- **2026-04** — Announced a CIDP study with argenx on April 7 and the Soleno-sponsored BRAVE-PWS caregiver study on April 15.
- **2026-05** — Listed IgAN and C3G research presentations at ISPOR US and National Kidney Foundation meetings.
- **2026-08** — Launched the six-month FSGS PULSE remote observational study on August 11.

## Links

- Website: https://www.foliahealth.com/
- LinkedIn: https://www.linkedin.com/company/folia-health/
- Twitter/X: https://twitter.com/foliahealth
- Instagram: https://www.instagram.com/foliahealth/
- Facebook: https://www.facebook.com/myfoliahealth

---

Profile page: https://yespress.io/folia-health-the-home-reported-outcomes-company
Published by YesPress — https://yespress.io
Last updated: 2026-10-04